Samsung Medison's TAI Ultrasound Technology for Fatty Liver Recognized as New Medical Technology

Samsung Medison's premium ultrasound diagnostic device for radiology equipped with TAI functionality, 'RS85 Prestige'

[Asia Economy Reporter Lee Gwanju] Samsung Medison announced on the 30th that its ultrasound technology 'TAI™' has been recognized as a new medical technology by the Korea Health Industry Development Institute based on the safety and efficacy evaluation results for quantitative examination of liver steatosis in non-alcoholic fatty liver disease.

TAI™ is a technology that measures the degree to which ultrasound signals are weakened by fat within liver cells to quantify fatty liver in real time. It allows patients suspected of non-alcoholic fatty liver disease to undergo a safe, non-invasive examination, reducing their burden, and provides stepwise values to medical staff to help determine the appropriate timing for treatment.

In a normal liver, fat is within 5%, but when more fat accumulates, it is called fatty liver. Fatty liver is classified into alcoholic fatty liver caused by excessive drinking and non-alcoholic fatty liver caused by metabolic diseases such as obesity, diabetes, and hyperlipidemia. Non-alcoholic fatty liver has a high risk of progressing to steatohepatitis, liver fibrosis, cirrhosis, and liver cancer, making early diagnosis important.

Hong Jinpyo, Head of the Health Medicine Division at Samsung Medical Center, said, "TAI™ will be an important indicator for patients suspected of non-alcoholic fatty liver to intuitively recognize the degree of fatty liver and actively engage in treatment," adding, "We are currently verifying whether to introduce it into the Samsung Medical Center health checkup program."

Samsung Medison plans to provide opportunities for direct experience by participating in the '2022 Korean Association of Private Practitioners Nationwide Tour Busan·Gyeongnam Seminar' held at BEXCO in Busan on the 2nd of next month and the '25th Korean Internal Medicine Society Autumn Academic Conference' held at Lotte Hotel in Sogong-dong on the 16th.

Yoo Gyutae, Executive Director of Samsung Medison's Strategic Marketing Team, said, "We are pleased to have developed technology needed by domestic and international medical staff for liver diseases, whose prevalence is recently increasing, and to have been recognized as a new medical technology," adding, "We will continue to do our best to introduce functions that support safe and accurate diagnosis by medical staff."

This content was produced with the assistance of AI translation services.